What is CDIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CDIO?

P/E (TTM) is n/a and 52-week range is $0.97 to $7.91 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CDIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CDIO?

The company profile lists revenue (TTM) near $15K, net income (TTM) near $-649M, EPS (TTM) near $-2.92 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cardio Diagnostics Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Chicago, Illinois, US, 3M shares outstanding, ISIN US14159C2026 when available from company profile and filing metadata.

Cardio Diagnostics Holdings Inc

$CDIO

Health Care · Biotechnology

IR Run Scenarios

$1.87

+0.54%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 15 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

Employees

Website

www.cardiodiagnosticsinc.com

IPO

2021-11-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)